×
Please click
here
if you are not redirected within a few seconds.
All
Images
Videos
News
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
Yahoo Finance
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company...
1 week ago
Implied Volatility Surging for Atea (AVIR) Stock Options
Yahoo Movies Canada
Investors need to pay close attention to Atea (AVIR) stock based on the movements in the options market lately.
2 days ago
Stock Quote & Chart | Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals
Today's High; $3.71: Today's Low; $3.65: 52 Week High; $5.19: 52 Week Low; $2.77. Data Provided by Refinitiv. Minimum 15 minutes delayed. Investor FAQs.
41 months ago
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant ...
Atea Pharmaceuticals
A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2...
3 months ago
Analyst Coverage
Atea Pharmaceuticals
Atea Pharmaceuticals, Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Atea Pharmaceuticals,...
41 months ago
Bain Capital Life Sciences Leads $215M Financing in Atea Pharmaceuticals
Choate Hall & Stewart LLP
Choate represented Bain Capital Life Sciences as lead investor in the $215 million Series D financing in Atea Pharmaceuticals.
47 months ago
Atea Pharmaceuticals (AVIR) Stock Forecast & Analyst Ratings
Moomoo
Free Atea Pharmaceuticals (AVIR) analysis tools, including analyst ratings and target price forecasts, help you make informed investment decisions.
1 month ago
Quarterly Reports | Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update · Fourth Quarter 2023 Financial Results...
41 months ago
Atea Pharmaceuticals Announces Closing of Initial Public Offering
Atea Pharmaceuticals
BOSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company...
42 months ago
Concentra rebounds with a shot at COVID-19-focused Atea
Fierce Biotech
Weeks after closing a deal to buy Jounce , Concentra is rebounding to pick up another struggling biotech, this time COVID-19-focused Atea...
11 months ago